The impact of comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients receiving EGFR-TKI therapy

Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as the standard first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, the impact of comorbidities and treatment toxicities on quality of life (QoL) was sel...

Full description

Bibliographic Details

Published in:	Journal of the Formosan Medical Association
Main Authors:	Jung-Yueh Chen, Sheng-Kai Liang, Tzu-Yi Chuang, Chia-Yu Chu, Chia-Hung Tu, Yu-Jo Yeh, Yu-Feng Wei, Kuan-Yu Chen
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Subjects:	Adverse events Comorbidity Epidermal growth factor receptor tyrosine kinase inhibitor Non-small cell lung cancer Quality of life Neutrophil-to-lymphocyte ratio
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664623002917